Intravitreal anti-vegf versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization

Retina

Volumn 30, Issue 3, 2010, Pages 418-424

  Yoon, Jong Uk ^a   Byun, Yeo Jue ^a   Koh, Hyoung Jun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Anti VEGF; Myopic CNV; PDT

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77949385793     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181bd2fe4     Document Type: Review

References (21)

1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
2. Yoshida T, Ohno-Matsui K, Ohtake Y, et al., Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109: 712-719.
3. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673.
4. Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: a prospective series of 1- and 2-year follow-up. Br J Ophthalmol 2004;88:1315-1319.
5. Rich RM, Rosenfeld PJ, Puliafito CA, et al., Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
6. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-1361.
7. Hahn R, Sacu S, Michels S, et al., Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration (in German). Ophthalmologe 2007;104:588-593.
8. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
9. Heier JS, Boyer DS, Ciulla TA, et al.; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124: 1532-1542.
10. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl Med 2006;355:1432-1444.
11. Ikuno Y, Sayanagi K, Soga K, et al., Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
12. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147:84-93.
13. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
14. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:311-318.
15. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: 1-year outcome. Br. J Ophthalmol 2009;93:448-451.
16. Yodoi Y, Tsujikawa A, Nakanishi H, et al., Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009; 147:816-824.
17. Hayashi K, Ohno-Matsui K, Teramukai S, et al., Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008;145:518-526.
18. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007;143:449-454.
19. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841-852.
20. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
21. Parodi MB, Da Pozzo S, Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 2007;85:50-54.